Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

被引：0
|
作者：
Othman, Jad [1 ,2 ,3 ]
Dillon, Richard [1 ,4 ]
机构：
[1] Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England
[2] Royal North Shore Hosp, Dept Haematol, Sydney, Australia
[3] Univ Sydney, Fac Med & Heath, Sydney, Australia
[4] Guys & St Thomas Hosp NHS Trust, Dept Haematol, London, England
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 07期
关键词：
INDUCTION CHEMOTHERAPY; ADULT PATIENTS; SURVIVAL;
D O I：
10.1016/S2352-3026(23)00092-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E478 / E479
页数：2
相关论文
共 50 条
  • [41] Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia
    Loghavi, Sanam
    DiNardo, Courtney D.
    Furudate, Ken
    Takahashi, Koichi
    Tanaka, Tomoyuki
    Short, Nicholas J.
    Kadia, Tapan
    Konopleva, Marina
    Kanagal-Shamanna, Rashmi
    Farnoud, Noushin R.
    Pierce, Sherry
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Patel, Keyur P.
    Daver, Naval
    Yilmaz, Musa
    Medeiros, L. Jeffrey
    Kantarjian, Hagop
    Ravandi, Farhad
    Wang, Sa A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (06) : 1054 - 1063
  • [42] Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach
    Petiti, Jessica
    Pignochino, Ymera
    Schiavon, Aurora
    Giugliano, Emilia
    Berrino, Enrico
    Giordano, Giorgia
    Itri, Federico
    Dragani, Matteo
    Cilloni, Daniela
    Lo Iacono, Marco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [43] LA1 NPM1-MUTATED-SPECIFIC T-CELL RESPONSES OCCURRING IN PATIENTS WITH NPM1-MUTATED ACUTE MYELOID LEUKEMIA
    Forghieri, F.
    Riva, G.
    Lagreca, I.
    Quadrelli, C.
    Paolini, A.
    Bigliardi, S.
    Morselli, M.
    Coluccio, V.
    Maccaferri, M.
    Colaci, E.
    Fantuzzi, V.
    Nasillo, V.
    Messerotti, A.
    Arletti, L.
    Pioli, V.
    Lugli, E.
    Gilioli, A.
    Zucchini, P.
    Vallerini, D.
    Barozzi, P.
    Bonacorsi, G.
    Cuoghi, A.
    Bresciani, P.
    Marasca, R.
    Basso, S.
    Liso, A.
    Comoli, P.
    Narni, F.
    Luppi, M.
    Potenza, L.
    HAEMATOLOGICA, 2016, 101 : S15 - S15
  • [44] Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia
    Doyen, Jerome
    Italiano, Antoine
    Peyrade, Frederic
    Bouyer, Claude
    Thyss, Antoine
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (05) : 744 - 745
  • [45] PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1
    Pianigiani, Giulia
    Betti, Camilla
    Bigerna, Barbara
    Rossi, Riccardo
    Brunetti, Lorenzo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (01) : 184 - 187
  • [46] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
    Stasi, Roberto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 527 - 540
  • [47] Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation
    Gu, Xiaorong
    Saunthararajah, Yogen
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : 578 - 581
  • [48] Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia
    Venanzi, Alessandra
    Cardinali, Valeria
    Perriello, Vincenzo
    Albano, Francesco
    Cimino, Gaetano
    Martino, Giovanni
    Marra, Andrea
    Sportoletti, Paolo
    Andresen, Vibeke
    Gjertsen, Bjorn T.
    Sica, Simona
    Chiusolo, Patrizia
    Martelli, Maria Paola
    Tiacci, Enrico
    Falini, Brunangelo
    AMERICAN JOURNAL OF HEMATOLOGY, 2024,
  • [49] NPM1 mutated acute myeloblastic leukaemia
    Bousquet, Marina
    HEMATOLOGIE, 2023, 29 (01): : 47 - 64
  • [50] Trials with gemtuzumab ozogamicin (Mylotarg®) combined with chemotherapy regimens in acute myeloid leukemia
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2002, 2 : S24 - S28
12345